CA Patent

CA3058375A1 — Niraparib compositions

Assigned to Merck Sharp and Dohme LLC · Expires 2018-10-04 · 8y expired

What this patent protects

The present disclosure relates to solid forms of 2-{4-[(3S)-piperidin-3-yl]phenyl}- 2H-indazole-7-carboxamide, also known as niraparib, which is useful in the treatment of cancer.

USPTO Abstract

The present disclosure relates to solid forms of 2-{4-[(3S)-piperidin-3-yl]phenyl}- 2H-indazole-7-carboxamide, also known as niraparib, which is useful in the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number: CA3058375A1
Jurisdiction: CA
Classification: —
Expires: 2018-10-04
Drug substance claim: No
Drug product claim: No
Assignee: Merck Sharp and Dohme LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.